SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
sc-12-0715_sm_SupplFigure1.pdf239KSuppl. Figure 1. Transduction with a control GFP lentiviral construct shows no significant differences in transduction efficiency between control (NHDF = neonatal human dermal fibroblasts) and FANCC fibroblasts.
sc-12-0715_sm_SupplFigure2.pdf220KSuppl. Figure 2. DNA fingerprinting of FANCC hiPSC (bottom panel) showing identical DNA genetic profiles with the fibroblast (upper panels) they were derived from respectively.
sc-12-0715_sm_SupplFigure3.pdf214KSuppl. Figure 3. FA functionality pathway assays measuring the number of FANCD2 foci in response to mitomycin C treatment. Representative images showing activation of FA pathway and red FANCD2 foci accumulation in control hESC and hiPSC. In contrary, no activation of FA pathway was observed in the FANCC hESC/hiPSC clones.
sc-12-0715_sm_SupplTable1.pdf423KSupplementary Table 1. Summary of hiPSC lines derived from FANC deficient patients together with reprogramming efficiency.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.